All In Biotech

Drug Trial Radar · NCT02164513

A Study Comparing the Efficacy, Safety and Tolerability of Fixed Dose Combination (FDC) of FF/UMEC/VI With the FDC of FF/VI and UMEC/VI; Administered Once-daily Via a Dry Powder Inhaler (DPI) in Subjects With Chronic Obstructive Pulmonary Disease (COPD)

A Phase III, 52 Week, Randomized, Double-blind, 3-arm Parallel Group Study, Comparing the Efficacy, Safety and Tolerability of the Fixed Dose Triple Combination FF/UMEC/VI With the Fixed Dose Dual Combinations of FF/VI and UMEC/VI, All Administered Once-daily in the Morning Via a Dry Powder Inhaler in Subjects With Chronic Obstructive Pulmonary Disease

Last checked: Nov 19, 2026Latest source record: Oct 10, 2018 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 10,355 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

10,355

Actual

Start

Jun 30, 2014

Primary completion

Jul 17, 2017

Study completion Jul 17, 2017

Sponsor

Lead sponsor
GlaxoSmithKlineGSK (GSK)
Sponsor type
Industry
First posted
Jun 16, 2014

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
Who can join
All sexes, from 40 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The study evaluates the efficacy of fluticasone furoate/umeclidinium bromide/vilanterol (FF/UMEC/VI) to reduce the annual rate of moderate and severe exacerbations compared with dual therapy of FF/VI or UMEC/VI in subjects with COPD. Published studies which assessed the use of an 'open' triple therapy (use of Inhaled Corticosteroid \[ICS\]/ Long-acting Muscarinic Receptor Antagonists \[LAMA\])/ Long Acting Beta-Agonist \[LABA\] delivered via multiple inhalers) in moderate-severe COPD patients, reported improvements in lung function, Health Related Quality of Life (HRQoL), hospitalization rates and rescue medication use, compared to dual therapy (ICS/LABA) or LAMA alone. These studies have also shown similar safety profile with dual or monotherapy doses for periods of up to one year. Given the clinical experience with FF, UMEC and VI, and that the associated risks with these compounds are anticipated from their known pharmacology, the potential benefit of a new therapy option in patients with moderate to severe COPD supports the further development of the closed triple combination (delivered via one inhaler). In the current study subjects meeting all inclusion/exclusion criteria will complete 2-week run-in period; 52 week treatment period and a 1-week safety follow-up period. Eligible subjects will be randomized to one of the following double-blind treatment groups FF/UMEC/VI 100 micrograms (mcg)/62.5 mcg/25 mcg once daily (QD), FF/VI 100 mcg/25 mcg QD, or UMEC/VI 62.5 mcg/25 mcg QD

Conditions

  • Pulmonary Disease, Chronic Obstructive

Interventions

  • fluticasone furoate (FF)Drug

    FF will be available in combination as dry powder for inhalation as FF/UMEC/VI 100 mcg/62.5 mcg/25 mcg and FF/VI 100 mcg/25 mcg

  • vilanterol (VI)Drug

    VI will be available in combination as dry powder for inhalation as FF/UMEC/VI 100 mcg/62.5 mcg/25 mcg, FF/VI 100 mcg/25 mcg and UMEC/VI 62.5 mcg/25 mcg

  • umeclidinium bromide (UMEC)Drug

    UMEC will be available in combination as dry powder for inhalation as FF/UMEC/VI 100 mcg/62.5 mcg/25 mcg, and UMEC/VI 62.5 mcg/25 mcg

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Annual Rate of On-treatment Moderate/Severe Exacerbations Comparing FF/UMEC/VI With UMEC/VI and FF/VITime frame: Up to Week 52

Locations

998 sites in 37 countries. Site status is shown where the registry gives one.

  • GSK Investigational Site

    Athens, Alabama

  • GSK Investigational Site

    Birmingham, Alabama

  • GSK Investigational Site

    Birmingham, Alabama

  • GSK Investigational Site

    Birmingham, Alabama

  • GSK Investigational Site

    Florence, Alabama

  • GSK Investigational Site

    Jasper, Alabama

  • GSK Investigational Site

    Mobile, Alabama

  • GSK Investigational Site

    Muscle Shoals, Alabama

  • GSK Investigational Site

    Sheffield, Alabama

  • GSK Investigational Site

    Chandler, Arizona

  • GSK Investigational Site

    Flagstaff, Arizona

  • GSK Investigational Site

    Glendale, Arizona

  • GSK Investigational Site

    Peoria, Arizona

  • GSK Investigational Site

    Phoenix, Arizona

  • GSK Investigational Site

    Phoenix, Arizona

  • GSK Investigational Site

    Tucson, Arizona

  • GSK Investigational Site

    Tucson, Arizona

  • GSK Investigational Site

    Tucson, Arizona

  • GSK Investigational Site

    Arcadia, California

  • GSK Investigational Site

    Bakersfield, California

  • GSK Investigational Site

    Chula Vista, California

  • GSK Investigational Site

    Encinitas, California

  • GSK Investigational Site

    Escondido, California

  • GSK Investigational Site

    Huntington Beach, California

  • GSK Investigational Site

    Long Beach, California

  • GSK Investigational Site

    Long Beach, California

  • GSK Investigational Site

    Mission Hills, California

  • GSK Investigational Site

    Modesto, California

  • GSK Investigational Site

    Newport Beach, California

  • GSK Investigational Site

    Palo Alto, California

  • GSK Investigational Site

    Reseda, California

  • GSK Investigational Site

    Riverside, California

  • GSK Investigational Site

    Rolling Hills Estates, California

  • GSK Investigational Site

    Sacramento, California

  • GSK Investigational Site

    San Diego, California

  • GSK Investigational Site

    Santa Ana, California

  • GSK Investigational Site

    Santa Monica, California

  • GSK Investigational Site

    Torrance, California

  • GSK Investigational Site

    Tustin, California

  • GSK Investigational Site

    Upland, California

Showing 40 of 998 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.